Support & Resources


KabiCare provides support to help patients access STIMUFEND® (pegfilgrastim-fpgk)

Our experts work closely with you and your staff to help make every step smoother, including enrolling in KabiCare, navigating patient insurance coverage and financial assistance, access to medication, patient disease education, injection training, refill reminders, and more.


     Enrollment support



     Financial support*



     Insurance support



     Clinical support


*Eligibility criteria apply.


Resources for STIMUFEND

Healthcare Common Procedure Coding System (HCPCS) code


Payment status indicator

Identifies whether a service represented by a CPT or HCPCS code is payable under the Outpatient Prospective Payment System (OPPS). Ambulatory Payment Classification (APC) or another payment system. Only 1 status indicator is assigned to each CPT or HCPCS code.


Check with the specific payer to verify additional coding and billing requirements for STIMUFEND®.


Download the Billing and Coding Guide

Filename
STIMUFEND-Billing-and-Coding-Guide-3500.pdf
Size
880 KB
Format
pdf
Download the Billing and Coding Guide

Healthcare Common Procedure Coding System (HCPCS) code


Payment status indicator

Identifies whether a service represented by a CPT or HCPCS code is payable under the Outpatient Prospective Payment System (OPPS). Ambulatory Payment Classification (APC) or another payment system. Only 1 status indicator is assigned to each CPT or HCPCS code.


Check with the specific payer to verify additional coding and billing requirements for STIMUFEND®.

Download the Billing and Coding Guide

Filename
STIMUFEND-billing-and-coding-guide.pdf
Size
1 MB
Format
pdf
Download the Billing and Coding Guide


Dosing and 
Administration Guide

Filename
STIMUFEND-Dosing-and-Administration-Guide-3565.pdf
Size
552 KB
Format
pdf
Dosing and 
Administration Guide

HCP STIMUFEND Brochure

Filename
STIMUFEND-HCP-Brochure-2316.pdf
Size
7 MB
Format
pdf
STIMUFEND HCP Brochure


Ordering Guide

Filename
STIMUFEND-Ordering-Guide-3989.pdf
Size
150 KB
Format
pdf
Ordering Guide

Coding and Billing Guide

Filename
STIMUFEND-Billing-and-Coding-Guide-3500.pdf
Size
880 KB
Format
pdf
Billing and Coding Guide

Sample Letter of Medical Necessity

Filename
STIMUFEND-Letter-of-Necessity-1940.docx
Size
30 KB
Format
docx
Letter of Medical Necessity

Sample Letter of Appeals

Filename
STIMUFEND-Letter of Appeal-1941.docx
Size
32 KB
Format
docx
Letter of Appeal

Experiencing a problem?

Fresenius Kabi may offer healthcare professionals a replacement for a STIMUFEND product that has been rendered unusable through unintentional, unplanned circumstances, including:

  • Product was mishandled, dropped, broken, used, or stored incorrectly

  • An unforeseen event caused damage to the product

  • There was an error in mixing or preparing the product

To request a replacement, download the Product Replacement Form or call Fresenius Kabi’s customer service line at (888) 386-1300.

Fresenius Kabi reserves the right to reject a request for a product replacement in accordance with its STIMUFEND product replacement policy. Product dispensed through a specialty pharmacy is not eligible for product replacement. Additional eligibility requirements and limitations apply. See Product Replacement Form for more details.


Ready to start the conversation?



An Account Manager is your best source for learning more about STIMUFEND. Connect with your specialist to schedule a meeting, ask questions, receive in-depth product information, or request formulary data for your patients.

An Account Manager is your best source for learning more about STIMUFEND. Connect with your Account Manager to schedule a meeting, ask questions, receive in-depth product information, or request formulary data for your patients.


An Account Manager is your best source for learning more about STIMUFEND. Connect with your Account Manager to schedule a meeting, ask questions, receive in-depth product information, or request formulary data for your patients.


Important Safety Information

Contraindication

  • Stimufend (pegfilgrastim-fpgk) is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
  • Reactions have included anaphylaxis

Splenic Rupture

  • Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products
  • Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain

Acute Respiratory Distress Syndrome (ARDS)

  • ARDS can occur in patients receiving pegfilgrastim products
  • Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving Stimufend
  • Discontinue Stimufend in patients with ARDS

Serious Allergic Reactions

  • Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products
  • The majority of reported events occurred upon initial exposure and can recur within days after the discontinuation of initial anti-allergic treatment
  • Permanently discontinue Stimufend in patients with serious allergic reactions

Use in Patients with Sickle Cell Disorders

  • In patients with sickle cell trait or disease, severe and sometimes fatal sickle cell crises can occur in patients receiving pegfilgrastim products
  • Discontinue Stimufend if sickle cell crisis occurs

Glomerulonephritis

  • Has occurred in patients receiving pegfilgrastim products
  • Diagnoses based on azotemia, hematuria, proteinuria, and renal biopsy
  • Generally, events resolved after dose-reduction or discontinuation of pegfilgrastim products
  • If suspected, evaluate for cause and if cause is likely, consider dose-reduction or interruption of Stimufend

Leukocytosis

  • Increased white blood cell counts of 100 x 109/L have been observed
  • Monitoring of complete blood count (CBC) during Stimufend therapy is recommended

Thrombocytopenia

  • Thrombocytopenia has been reported in patients receiving pegfilgrastim products. Monitor platelet counts

Capillary Leak Syndrome (CLS)

  • CLS has been reported after G-CSF administration, including pegfilgrastim products
  • Characterized by hypotension, hypoalbuminemia, edema and hemoconcentration
  • Episodes vary in frequency, severity and may be life-threatening if treatment is delayed
  • Patients with symptoms should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care

Potential for Tumor Growth Stimulatory Effects on Malignant Cells

  • G-CSF receptor has been found on tumor cell lines
  • The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded.

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer

  • MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.

Aortitis

  • Aortitis has been reported in patients receiving pegfilgrastim products. It may occur as early as the first week after start of therapy
  • Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count)
  • Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue Stimufend if aortitis is suspected

Nuclear Imaging

  • Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results

Most common adverse reactions

  • Bone pain
  • Pain in extremity

Indications and Usage
Stimufend is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Stimufend is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).
Limitations of Use
Stimufend is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Please see Stimufend Full Prescribing Information.
Stimufend Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.

Indications

Stimufend is indicated to:

  • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
  • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome)

Limitations of Use


Stimufend is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.